News & Press Releases
10.30.2023
ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
09.20.2023
ArriVent Appoints Chris Nolet to its Board of Directors
09.10.2023
Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC
09.10.2023
Allist and Arrivent Announce interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer
07.13.2023
InnoCare and ArriVent Announce Clinical Development Collaboration
03.27.2023
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
07.05.2022
ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations
02.15.2022
ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
12.31.2021
Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
06.30.2021
ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset